FREQUENTLY Asked Questions

What should IRBs do when reviewing the types of IVD studies that are the focus of this guidance?

View All FAQs
About the Author
Proxima CRO Team
Isabella Schmitt, RAC
Director of Regulatory Affairs
Ms. Schmitt has also served in additional regulatory affairs and clinical research roles in which she contributed to multiple regulatory submissions and clinical affairs projects across a wide range of indications.

To facilitate IVD device development, FDA intends to exercise enforcement discretion toward IRBs who approve IVD investigations that are consistent with the factors, with respect to the IRB's duties under 21 CFR part 56 regarding informed consent for those studies. (Noncompliance with requirements of 21 CFR part 56 not related to informed consent is not subject to enforcement discretion.) FDA recommends that the IRB review the sponsor's documentation regarding the factors described, including the policies and procedures followed by the specimen provider to ensure that the subject cannot be identified. IRBs should apply existing FDA regulations, including all informed consent requirements, to any other investigational IVD study. FDA encourages IRBs to contact FDA if they have questions about the guidance or a specific study under review.

The factors being mentioned can be viewed here.

Related FAQs:
More Questions? We're here to help!
SPEAK WITH A SPECIALIST